Lenvatinib is a receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma. Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
- Mechanism
- Curator reviewed
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
- Primary indication
- Lenvatinib is indicated for the treatment of the following cancerous conditions: Differentiated Thyroid Cancer (DTC) Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer Renal Cell Carcinoma (RCC) First-line treatment, in combination...Curator reviewed · 6 structured indications
- Formula / weight
- C21H19ClN4O4 · 426.86 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2015 · European Union, 2020
- Code names
- E-7080 · ER-203492-00 · MK-7902
- Brand names
Resolves to
WOSKHXYHFSIKNG-UHFFFAOYSA-NSMILESCOC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Lenvatinib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account